"FDA Response to three Citizen Petitions against biosimilars" (PDF), FDA , 30 May 2006, archived from the original (PDF) on June 19, 2006, retrieved 23 November 2015 In 2023, the FDA approved a different sustained-release form of growth hormone, Sogroya (somapacitan-beco) (Novo) for both pediatric patients (2.5 years and older) and adult patients, whom have growth failure due to inadequate secretion of endogenous growth hormone (rHGH)
However, there are some important factors to be aware of before deciding on moving forward with B12 injections
Routine rechecking of serum B12 levels is not generally recommended for patients on regular injections as levels will be artificially high
even in patients treated for years with conventional doses of folic acid, the serum levels of vitamin B12 are found to be low
As a peptide fragment, behaviour may differ from full-length growth hormone in receptor or signalling assays
Immune system reinforcement